Grufity logoGrufity logo
StocksFundsSearch Filings

Silk Road Medical Inc Stock Research

SILK

30.19USD-0.03(-0.10%)Market Closed

Market Summary

USD30.19-0.03
Market Closed
-0.10%

SILK Alerts

SILK Stock Price

SILK RSI Chart

SILK Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-21.33

Price/Sales (Trailing)

7.75

EV/EBITDA

-29.47

Price/Free Cashflow

-35.17

SILK Price/Sales (Trailing)

SILK Profitability

Return on Equity

-33.57%

Return on Assets

-20.4%

Free Cashflow Yield

-2.84%

SILK Fundamentals

SILK Revenue

Revenue (TTM)

150.7M

Revenue Y/Y

43.22%

Revenue Q/Q

0.15%

SILK Earnings

Earnings (TTM)

-54.8M

Earnings Y/Y

1.31%

Earnings Q/Q

-30.49%

Price Action

52 Week Range

29.2058.04
(Low)(High)

Last 7 days

-6.6%

Last 30 days

-31.7%

Last 90 days

-34.7%

Trailing 12 Months

-9.1%

SILK Financial Health

Current Ratio

10.41

SILK Investor Care

Shares Dilution (1Y)

10.36%

Diluted EPS (TTM)

-1.49

Peers (Alternatives to Silk Road Medical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.11% 17.93%
46.98
6.01
8.73% 30.37%
107.9B
6.4B
1.59% 35.23%
82.22
16.77
8.89% -20.19%
74.1B
13.0B
-2.50% 25.53%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-8.88% -4.13%
44.09
3.79
-1.96% -15.83%
51.0B
5.5B
-3.79% -16.48%
34.28
9.28
2.68% -3.23%
MID-CAP
7.2T
557.2M
-4.80% 67.52%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.66% 109.19%
1.8K
13.24
13.08% 200.12%
5.9B
1.1B
-6.80% -18.72%
34.14
5.75
11.20% 53.04%
3.5B
430.0M
-14.11% -18.87%
-33.26
8.1
26.13% 15.73%
1.7B
794.7M
-34.98% -61.87%
-8.24
2.11
7.73% -3556.34%
SMALL-CAP
1.7B
389.0M
2.85% 97.40%
-11.25
4.42
44.08% 6.96%
1.2B
150.7M
-31.68% -9.12%
-21.33
7.75
40.31% 1.80%
1.1B
814.3M
-18.01% -14.60%
25.63
1.4
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Silk Road Medical

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue8.7%150,749138,638126,833114,160107,443
Gross Profit8.1%108,924100,76292,70383,26278,959
Operating Expenses6.0%161,884152,766146,139140,763132,218
  S&GA Expenses5.9%123,125116,317111,391107,619102,468
  R&D Expenses6.3%38,75936,44934,74833,14429,750
EBITDA0.9%-46,892-47,295---
EBITDA Margin6.7%-0.41*-0.44*---
EBT Margin5.9%-0.44*-0.46*---
Interest Expenses21.0%6,1705,0984,0002,9192,516
Net Income0.4%-54,791-55,010-57,089-60,655-55,796
Net Income Margin11.8%-0.40*-0.45*-0.53*-0.52*-
Free Cahsflow20.8%-37,586-47,479-49,991-48,451-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-3.7%260270163163143
  Current Assets-9.7%230255147147128
    Cash Equivalents-8.6%51.0055.0051.0088.0094.00
  Inventory-10.9%17.0019.0020.0018.0018.00
  Net PPE-5.1%9.009.0010.0010.0010.00
Liabilities-3.6%10210610510375.00
  Current Liabilities-14.8%21.0024.0024.0021.0029.00
.    Short Term Borrowings-10.00----
    LT Debt, Non Current0.3%75.0075.0074.0074.0039.00
Shareholder's Equity-3.8%15816457.0060.0068.00
  Retained Earnings-4.8%-360-343-331-320-305
  Additional Paid-In Capital2.0%518508388381373
Shares Outstanding0.9%39.0038.0035.0035.0035.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations7.9%-30.00-32.58-41.29-43.06-41.69
  Share Based Compensation15.4%29.0025.0021.0019.0016.00
Cashflow From Investing5.0%-153-162-42.87-2.0034.00
Cashflow From Financing0.7%14114030.0031.006.00

Risks for SILK

What is the probability of a big loss on SILK?

90.0%


Probability that Silk Road Medical stock will be more than 20% underwater in next one year

87.2%


Probability that Silk Road Medical stock will be more than 30% underwater in next one year.

42.9%


Probability that Silk Road Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SILK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Silk Road Medical was unfortunately bought at previous high price.

Drawdowns

Returns for SILK

Cumulative Returns on SILK

-7.6%


3-Year Cumulative Returns

Which funds bought or sold SILK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
sold off
-100
-255,160
-
-%
2023-05-23
BROOKFIELD Corp /ON/
sold off
-100
-1,004,150
-
-%
2023-05-22
AMERIPRISE FINANCIAL INC
added
1.01
-1,065,360
3,162,640
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-73.87
-3,218,000
772,000
-%
2023-05-18
JPMORGAN CHASE & CO
added
99.87
2,608,000
8,040,000
-%
2023-05-17
Thrivent Financial for Lutherans
added
2.53
-5,359,000
16,889,000
0.04%
2023-05-17
Advisory Services Network, LLC
reduced
-94.13
-325,351
14,791
-%
2023-05-16
Rockefeller Capital Management L.P.
sold off
-100
-225,000
-
-%
2023-05-16
Baker Avenue Asset Management, LP
unchanged
-
-206
587
-%
2023-05-16
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
added
1.58
-17,690,800
53,673,300
0.16%

1–10 of 46

Latest Funds Activity

Are funds buying SILK calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SILK
No. of Funds

Silk Road Medical News

Simply Wall St
Shareholders in Silk Road Medical (NASDAQ:SILK) have lost 22%, as stock drops 6.6% this past week.
Simply Wall St,
79 minutes ago
Scene for Dummies: Everything Hollywood Undead
Carotid Stenting Systems Market Statistical Forecast, Trade Analysis ....
Scene for Dummies: Everything Hollywood Undead,
5 days ago
InvestorsObserver
Yahoo Finance
StreetInsider.com
Form S-3ASR Silk Road Medical Inc.
StreetInsider.com,
17 days ago
Santa Maria Times

Schedule 13G FIlings of Silk Road Medical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 10, 2023
wasatch advisors lp
-
0
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
6.9%
2,616,795
SC 13G/A
Feb 13, 2023
capital world investors
7.8%
2,966,730
SC 13G/A
Feb 10, 2023
flynn james e
3.66%
1,396,640
SC 13G/A
Feb 09, 2023
vanguard group inc
9.34%
3,562,110
SC 13G/A
Feb 08, 2023
wasatch advisors inc
-
0
SC 13G/A
Jan 31, 2023
blackrock inc.
7.0%
2,664,762
SC 13G/A
Apr 11, 2022
alliancebernstein l.p.
10.7%
3,747,528
SC 13G/A
Feb 14, 2022
alliancebernstein l.p.
8.6%
2,988,334
SC 13G/A
Feb 11, 2022
capital world investors
10.0%
3,476,630
SC 13G/A

SILK Fair Value

Show Fair-Value

Recent SEC filings of Silk Road Medical

View All Filings
Date Filed Form Type Document
May 30, 2023
SD
SD
May 15, 2023
S-3ASR
S-3ASR
May 12, 2023
4
Insider Trading
May 12, 2023
RW
RW
May 11, 2023
144
Notice of Insider Sale Intent
May 10, 2023
SC 13G/A
Major Ownership Report
May 09, 2023
10-Q
Quarterly Report
May 09, 2023
8-K
Current Report
May 09, 2023
S-3
S-3
May 03, 2023
4
Insider Trading

Latest Insider Trading transactions for SILK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-11
Rogers Erica J.
acquired
4,800
1.6
3,000
president and ceo
2023-05-11
Rogers Erica J.
sold
-106,530
35.51
-3,000
president and ceo
2023-05-01
Davis Andrew S.
sold
-300,593
44.5125
-6,753
chief commercial officer
2023-05-01
Davis Andrew S.
acquired
39,844
5.90032
6,753
chief commercial officer
2023-04-17
WEATHERMAN ELIZABETH H
sold
-209,550
41.91
-5,000
-
2023-04-11
Rogers Erica J.
sold
-238,635
39.7725
-6,000
president and ceo
2023-04-11
Rogers Erica J.
acquired
9,600
1.6
6,000
president and ceo
2023-04-03
Davis Andrew S.
acquired
32,372
4.79376
6,753
chief commercial officer
2023-04-03
Davis Andrew S.
sold
-266,203
39.42
-6,753
chief commercial officer
2023-03-15
WEATHERMAN ELIZABETH H
sold
-209,550
41.91
-5,000
-

1–10 of 50

Erica J. Rogers
350
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

SILK Income Statement

2023-03-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Condensed Statements of Operations and Comprehensive Loss [Abstract]  
Revenue$ 40,131$ 28,021
Cost of goods sold12,5268,577
Gross profit27,60519,444
Operating expenses:  
Research and development10,4338,123
Selling, general and administrative34,08227,275
Total operating expenses44,51535,398
Loss from operations(16,910)(15,954)
Interest income2,28712
Interest expense(1,693)(621)
Other income (expense), net(144)(116)
Net loss(16,460)(16,679)
Other comprehensive loss:  
Change in unrealized gain (loss) on investments, net249 
Net change in other comprehensive loss249 
Net loss and comprehensive loss$ (16,211)$ (16,679)
Net loss per share, basic$ (0.43)$ (0.48)
Net loss per share, diluted$ (0.43)$ (0.48)
Weighted average common shares used to compute net loss per share, basic38,532,20235,023,297
Weighted average common shares used to compute net loss per share, diluted38,532,20235,023,297

SILK Balance Sheet

2023-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 50,427$ 55,358
Short-term investments138,640158,316
Accounts receivable, net19,95618,007
Inventories17,18219,293
Prepaid expenses and other current assets4,0493,924
Total current assets230,254254,898
Long-term investments15,285 
Property and equipment, net8,8979,372
Restricted cash155155
Other non-current assets4,9965,260
Total assets259,587269,685
Current liabilities:  
Accounts payable5,2722,523
Accrued liabilities15,59821,965
Total current liabilities20,87024,488
Long-term debt74,84874,596
Other liabilities6,2566,726
Total liabilities101,974105,810
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at March 31, 2023 and December 31, 2022 Shares issued and outstanding: none at March 31, 2023 and December 31, 2022
Common stock, $0.001 par value Shares authorized: 100,000,000 at March 31, 2023 and December 31, 2022 Shares issued and outstanding: 38,708,441 and 38,355,972 at March 31, 2023 and December 31, 2022, respectively3938
Additional paid-in capital517,663507,715
Accumulated other comprehensive income (loss)83(166)
Accumulated deficit(360,172)(343,712)
Total stockholders’ equity157,613163,875
Total liabilities and stockholders’ equity$ 259,587$ 269,685